Literature DB >> 22869327

Targeted therapies: STAT3 and EGFR target resistance.

Rebecca Kirk.   

Abstract

Entities:  

Year:  2012        PMID： 22869327     DOI： 10.1038/nrclinonc.2012.140

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.

Authors:  Malabika Sen; Sonali Joyce; Mary Panahandeh; Changyou Li; Sufi M Thomas; Jessica Maxwell; Lin Wang; William E Gooding; Daniel E Johnson; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2012-07-23       Impact factor: 12.531
  1 in total
  2 in total

1.  The STAT3 inhibitor pimozide impedes cell proliferation and induces ROS generation in human osteosarcoma by suppressing catalase expression.

Authors:  Nan Cai; Wei Zhou; Lan-Lan Ye; Jun Chen; Qiu-Ni Liang; Gang Chang; Jia-Jie Chen
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

2.  Stat3 upregulates leucine-rich repeat-containing g protein-coupled receptor 4 expression in osteosarcoma cells.

Authors:  Jia Liu; Wei Wei; Chang-An Guo; Ning Han; Jian-feng Pan; Teng Fei; Zuo-qin Yan
Journal:  Biomed Res Int       Date:  2013-12-25       Impact factor: 3.411
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.